Elanco Animal Health Incorporated (ELAN) Insider Trading Activity

NYSE$23.63
Market Cap
$11.8B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
140 of 870
Rank in Industry
3 of 44

ELAN Insider Trading Activity

ELAN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,137,688
6
100
Sells
$0
0
0

Related Transactions

Simmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
2
$578,338
0
$0
$578,338
Kurzius Lawrence Erikdirector
1
$213,000
0
$0
$213,000
Modi Rajeev A.SEE REMARKS
2
$195,924
0
$0
$195,924
VanHimbergen Robert MEVP and CFO
1
$150,427
0
$0
$150,427

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Insider Activity of Elanco Animal Health Incorporated

Over the last 12 months, insiders at Elanco Animal Health Incorporated have bought $1.14M and sold $0 worth of Elanco Animal Health Incorporated stock.

On average, over the past 5 years, insiders at Elanco Animal Health Incorporated have bought $1.99M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Simmons Jeffrey N (PRESIDENT, CEO AND DIRECTOR) — $578,338. Kurzius Lawrence Erik (director) — $213,000. Modi Rajeev A. (SEE REMARKS) — $195,924.

The last purchase of 4,971 shares for transaction amount of $99,843 was made by Simmons Jeffrey N (PRESIDENT, CEO AND DIRECTOR) on 2026‑05‑15.

List of Insider Buy and Sell Transactions, Elanco Animal Health Incorporated

2026-05-15PurchaseSimmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
4,971
0.001%
$20.09
$99,843
+16.72%
2026-05-15PurchaseModi Rajeev A.SEE REMARKS
4,911
0.001%
$20.35
$99,939
+16.72%
2025-12-12PurchaseKurzius Lawrence Erikdirector
10,000
0.002%
$21.30
$213,000
+11.18%
2025-12-11PurchaseSimmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
22,000
0.0045%
$21.75
$478,496
+11.24%
2025-12-11PurchaseVanHimbergen Robert MEVP and CFO
6,950
0.0014%
$21.64
$150,427
+11.24%
2025-12-11PurchaseModi Rajeev A.SEE REMARKS
4,500
0.0009%
$21.33
$95,985
+11.24%
2025-03-11PurchaseKurzius Lawrence Erikdirector
10,000
0.0021%
$10.20
$102,000
+84.56%
2025-03-07PurchaseKurzius Lawrence Erikdirector
10,000
0.002%
$10.90
$109,000
+65.53%
2025-03-05PurchaseHOOVER R DAVIDdirector
25,000
0.005%
$10.90
$272,558
+69.86%
2024-08-22PurchaseHarrington Michael Jdirector
3,500
0.0007%
$14.85
$51,974
-11.91%
2024-08-12PurchaseSimmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
100,000
0.02%
$13.01
$1.3M
-1.68%
2024-05-21PurchaseDOYLE WILLIAM Fdirector
15,000
0.0031%
$16.98
$254,700
-23.41%
2024-03-08PurchaseHarrington Michael Jdirector
3,100
0.0006%
$16.29
$50,494
-17.75%
2024-03-08PurchaseDOYLE WILLIAM Fdirector
15,000
0.003%
$16.30
$244,500
-17.75%
2024-03-06PurchaseHOOVER R DAVIDdirector
20,000
0.0041%
$16.14
$322,808
-15.48%
2023-03-14PurchaseHOOVER R DAVIDdirector
5,000
0.001%
$9.55
$47,750
+22.66%
2023-03-13PurchaseHOOVER R DAVIDdirector
5,000
0.001%
$9.46
$47,288
+23.84%
2023-03-10PurchaseSimmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
15,000
0.0031%
$9.60
$143,972
+19.49%
2023-03-03PurchaseHOOVER R DAVIDdirector
10,000
0.002%
$11.13
$111,300
+1.49%
2022-11-11PurchaseBILBREY JOHN Pdirector
7,500
0.0015%
$13.24
$99,267
-16.77%
Total: 78
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
171971
0.0344%
$4.06M90
<0.0001%
Modi Rajeev A.SEE REMARKS
160812
0.0322%
$3.8M30
<0.0001%
Kurzius Lawrence Erikdirector
131773
0.0264%
$3.11M40
+47.4%
VanHimbergen Robert MEVP and CFO
124233
0.0249%
$2.94M10
BAYER AKTIENGESELLSCHAFT10 percent owner
18446429
3.6934%
$435.89M01
HOOVER R DAVIDdirector
210000
0.042%
$4.96M240
<0.0001%
Harrington Michael Jdirector
81094
0.0162%
$1.92M60
<0.0001%
DOYLE WILLIAM Fdirector
76330
0.0153%
$1.8M20
<0.0001%
BILBREY JOHN Pdirector
41722
0.0084%
$985,890.8660
<0.0001%
Hicks Michael-BryantSee Remarks
33936
0.0068%
$801,907.6820
<0.0001%
Anand Kapila Kdirector
27467
0.0055%
$649,045.2130
<0.0001%
Kinard David SSee Remarks
22569
0.0045%
$533,305.4720
<0.0001%
LIN SARENA SSee Remarks
20000
0.004%
$472,600.0010
<0.0001%
Herendeen Paul
17307
0.0035%
$408,964.4110
<0.0001%
GARCIA ART Adirector
16465
0.0033%
$389,067.9520
+12.26%
Schacht Aaron LSee Remarks
13924
0.0028%
$329,024.1220
<0.0001%
Cabral Ramiro MartinSee Remarks
12741
0.0026%
$301,069.8320
<0.0001%
YOUNG TODD S.See Remarks
5000
0.001%
$118,150.0020
+15.95%
Kochevar Deborah Turnerdirector
3783
0.0008%
$89,392.2910
<0.0001%
Urbanek David AlanSee Remarks
76
0%
$1,795.8830
<0.0001%
Meer James MChief Accounting Officer
225
0%
$5,316.7510
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$910,099,463
123
11.52%
$2.01B
Elanco Animal Health Incorporated
(ELAN)
$25,613,591
65
-3.30%
$11.8B
$218,350,131
64
16.68%
$650.75M
$14,599,168
59
12.79%
$1.84B
$102,709,455
46
30.55%
$894.87M
$11,542,910
40
56.19%
$1.24B
$73,406,903
39
-5.33%
$1.5B
$21,020,549
38
-2.84%
$16.48B
$12,998,723
30
3.46%
$4.39B
$6,506,230
27
-16.20%
$1.02B
$78,335,024
20
4.77%
$33.3B
$83,406,412
19
21.96%
$2.6B
$2,769,748
17
-1.91%
$18.49B
$1,843,996
10
22.92%
$870.39M
$1,718,514
9
38.13%
$590.84M
$26,633,903
9
42.23%
$1.08B
$141,200
8
41.74%
$6.57B
$725,133
7
30.62%
$1.31B
$32,954,224
5
-0.22%
$39.81B

ELAN Institutional Investors: Active Positions

Increased Positions278+62.9%32M+5.59%
Decreased Positions191-43.21%64M-11.28%
New Positions119New9MNew
Sold Out Positions42Sold Out8MSold Out
Total Postitions529+19.68%539M-5.69%

ELAN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Dodge & Cox$1.86M16.65%82.76M-135,395-0.16%2025-09-30
Fmr Llc$1.47M13.15%65.36M+473,983+0.73%2025-09-30
Primecap Management Co/Ca/$1.13M10.05%49.96M-2M-3.49%2025-09-30
Vanguard Group Inc$1.09M9.78%48.59M+759,623+1.59%2025-09-30
Blackrock, Inc.$1.04M9.29%46.18M+23M+100.15%2025-09-30
T. Rowe Price Investment Management, Inc.$709,606.006.34%31.51M+12M+61.14%2025-09-30
Dimensional Fund Advisors Lp$556,439.004.97%24.71M+2M+8.63%2025-09-30
Ubs Group Ag$370,863.003.31%16.47M+6M+56.74%2025-09-30
State Street Corp$343,335.003.07%15.25M+6M+67.04%2025-09-30
Black Creek Investment Management Inc.$281,105.002.51%12.48M-7M-35.16%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.